Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
IPO Year: 2020
Exchange: NASDAQ
Website: immunome.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/1/2025 | $36.00 | Buy | Truist |
| 9/22/2025 | $26.00 | Buy | Goldman |
| 9/5/2025 | $26.00 | Buy | Craig Hallum |
| 4/2/2025 | $23.00 | Buy | Lake Street |
| 11/8/2024 | $30.00 | Overweight | Stephens |
| 5/31/2024 | $27.00 | Overweight | Piper Sandler |
| 4/30/2024 | $24.00 | Overweight | JP Morgan |
| 4/15/2024 | $35.00 | Buy | Guggenheim |
| 1/29/2024 | $30.00 | Outperform | Leerink Partners |
| 12/19/2023 | $12.00 | Outperform | Wedbush |
Fastest customizable press release news feed in the world
Immunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of $21.50 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $400 million. In addition, Immunome has granted the underwriters a 30-day option to purchase up to an additional 2,793,750 shares of its common stock at the public offering price, less
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology breakthroughs[1]. This momentum is already materializing, with five major oncology approvals secured in November across multiple cancer indications, demonstrating regulators' willingness to green-light promising therapies when supported by compelling clinical data[2]. Against this backdrop of regulatory evolution, several clinical-stage biotechs are advancing toward definitive registration studies and commercial readiness, po
Immunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $400 million of shares of its common stock. All of the shares are being offered by Immunome. In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of its common stock. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. Leer
Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints, with varegacestat delivering an objective response rate of 56% Varegacestat was generally well tolerated with a manageable safety profile New Drug Application submission to U.S. FDA planned for Q2 2026 Company to host conference call today at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacest
Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors. Webcast, Presentation Slides and Conference Call Information Immunome will host a webcast and conference call on Monday, December 15, 2025, at 8:30 a.m. ET / 5:30 a.m. PT to disc
Immunome, Inc. (the "company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 1, 2025, the Compensation Committee of the company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 88,000 shares of common stock to four new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will participate in the following investor conferences: Piper Sandler 37th Annual Healthcare Conference Presentation Date/Time: December 3, 2025, at 9 a.m. ET 8th Annual Evercore Healthcare Conference Presentation Date/Time: December 3, 2025, at 9:10 a.m. ET Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company's website at www.immunome.com. Replay webcasts will be available for approximately 30 days following the live presentation
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended September 30, 2025, and provided a business update. "Immunome's pipeline continues to advance," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. "We anticipate the release of topline data for the RINGSIDE trial of varegacestat before the end of this year, to be followed by an NDA submission if warranted." "I am particularly pleased to share that we have observed objective responses at multiple dose levels in B-cell lymphoma patients treated with IM-1021. The clinical ac
Immunome, Inc. (the "company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Nov. 3, 2025, the Compensation Committee of the company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 19,000 shares of common stock to three new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $17.
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 2nd Annual Guggenheim Healthcare Innovation Conference on Tuesday, Nov. 11, 2025 at 8:30 a.m. ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
8-K - Immunome Inc. (0001472012) (Filer)
424B5 - Immunome Inc. (0001472012) (Filer)
424B5 - Immunome Inc. (0001472012) (Filer)
8-K - Immunome Inc. (0001472012) (Filer)
10-Q - Immunome Inc. (0001472012) (Filer)
8-K - Immunome Inc. (0001472012) (Filer)
SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)
10-Q - Immunome Inc. (0001472012) (Filer)
8-K - Immunome Inc. (0001472012) (Filer)
SCHEDULE 13G - Immunome Inc. (0001472012) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Truist initiated coverage of Immunome with a rating of Buy and set a new price target of $36.00
Goldman initiated coverage of Immunome with a rating of Buy and set a new price target of $26.00
Craig Hallum initiated coverage of Immunome with a rating of Buy and set a new price target of $26.00
Lake Street initiated coverage of Immunome with a rating of Buy and set a new price target of $23.00
Stephens initiated coverage of Immunome with a rating of Overweight and set a new price target of $30.00
Piper Sandler initiated coverage of Immunome with a rating of Overweight and set a new price target of $27.00
JP Morgan initiated coverage of Immunome with a rating of Overweight and set a new price target of $24.00
Guggenheim initiated coverage of Immunome with a rating of Buy and set a new price target of $35.00
Leerink Partners initiated coverage of Immunome with a rating of Outperform and set a new price target of $30.00
Wedbush initiated coverage of Immunome with a rating of Outperform and set a new price target of $12.00
This live feed shows all institutional transactions in real time.
SC 13G/A - Immunome Inc. (0001472012) (Subject)
SC 13G - Immunome Inc. (0001472012) (Subject)
SC 13G - Immunome Inc. (0001472012) (Subject)
SC 13G/A - Immunome Inc. (0001472012) (Subject)
SC 13G/A - Immunome Inc. (0001472012) (Subject)
SC 13G/A - Immunome Inc. (0001472012) (Subject)
SC 13D/A - Immunome Inc. (0001472012) (Subject)
SC 13G/A - Immunome Inc. (0001472012) (Subject)
SC 13G - Immunome Inc. (0001472012) (Subject)
SC 13G - Immunome Inc. (0001472012) (Subject)
Live Leadership Updates
PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS
Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately. "We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today the appointment of Dr. Purnanand Sarma, PhD, as Chair of its Board of Directors. Dr. Sarma, who will hold the title of Executive Chairman, will actively support the strategic development of STALICLA, working closely with the CEO, Lynn Durham, and the management team. With an
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as Chief Technical Officer. Dr. Tsai has nearly three decades of experience in product development, process optimization, and manufacturing, particularly in the area of antibody-drug conjugates (ADCs). "Immunome is excited to add Phil to our management team as we advance our pipeline of differentiated targeted cancer therapies," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "With the Phase 3 trial of AL102 for the treatment of desmoid tumors fully enrolled, two IND filings p
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate and business development, alliance management, and commercial strategy. "Immunome is excited to welcome Kinney to our executive team as we advance our broad pipeline of targeted therapies," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "With the recent acquisition of AL102, Immunome is now a clinical stage company, and Kinney's expertise in navigating the complex business l
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors. Dr. Swain has over 30 years of oncology clinical research experience and has served on both public company and non-profit boards. "Immunome is pleased to welcome Sandra to the Board of Directors, especially given her extensive experience as a successful clinical researcher," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "Her deep understanding of oncology and patient care will add a valuable perspective as we advance AL102 through Phase 3 an
AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Roberts as Chief Technical Officer. Mr. Roberts has over three decades of experience in product development, global manufacturing, and commercialization of novel pharmaceutical products. "Immunome is delighted to add Phil to our management team as we advance our portfolio of immunotherapies, radioligand therapies, and ADCs towards clinical development," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "With an ambitious pipeline that spans multiple modalities, Phil's technical leadership
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Carol A. Schafer to its Board of Directors. Ms. Schafer has more than 25 years of experience in investment banking and equity capital markets and has served as a corporate director for multiple public companies. "Carol's financial expertise, strategic insight and understanding of equity markets will greatly benefit Immunome as we continue to expand and advance our pipeline of targeted oncology therapeutics," stated Clay B. Siegall, Ph.D., Chairman and Chief Executive Officer of Immunome. "The Immunome leadership team wil
Live finance-specific insights
Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints, with varegacestat delivering an objective response rate of 56% Varegacestat was generally well tolerated with a manageable safety profile New Drug Application submission to U.S. FDA planned for Q2 2026 Company to host conference call today at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacest
Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors. Webcast, Presentation Slides and Conference Call Information Immunome will host a webcast and conference call on Monday, December 15, 2025, at 8:30 a.m. ET / 5:30 a.m. PT to disc
- IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked and novel tumor antigens for patients in need of new cancer therapies. - IsoBio has closed its initial Series Seed financing round, raising $5 million from ASP Isotopes Inc. (ASPI). - The strategic collaboration contemplates future manufacturing opportunities for PET Labs (ASPI's nuclear medicine subsidiary). - IsoBio plans to leverage the technology and global manufacturing capabilities developed by ASPI to reduce the uncertainty of isotope supply chain/manufacturi
Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments. "2023 was a transformative year for Immunome as we closed the merger with Morphimmune, advanced our pipeline and expanded the company's leadership team," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Th
- Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - - Bob Lechleider, M.D., appointed as Chief Medical Officer – - Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors - - Cash runway expected to extend into Q1 2026* - Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update. "Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response," stated Purnanand Sarma, Ph.D., President and CEO of Immunome. "We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our p
Immunome, Inc. (NASDAQ:IMNM), a clinical stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. "We look forward to completing our clinical trial for IMM-BCP-01, our COVID-19 antibody program, while continuing to expand our oncology portfolio including our planned submission of the IND for IMM-ONC-01 by mid-2023. Our Discovery Engine provides unique insights into how the human immune system sees disease and continues to highlight interesting areas of cancer biology and identify novel targets an